Cite

HARVARD Citation

    Burtness, B. et al. (n.d.). LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals of oncology. p. . [Online]. 
  
Back to record